The treatment of hepatic encephalopathy

被引:40
作者
Morgan, Marsha Y.
Blei, A.
Gruengreiff, K.
Jalan, R.
Kircheis, G.
Marchesini, G.
Riggio, O.
Weissenborn, Karin
机构
[1] UCL, Ctr Hepatol, Div Med, Royal Free & Univ Coll Med Sch, London NW3 2PF, England
[2] Northwestern Univ, Chicago, IL 60611 USA
[3] UCL, Inst Hepatol, Div Med, Royal Free & Univ Coll Med Sch, London, England
[4] Univ Dusseldorf, Dept Gastroenterol Hepatol & Infectiol, D-4000 Dusseldorf, Germany
[5] Alma Mater Studiorum Univ, Unit Clin Dietet, Bologna, Italy
[6] Univ Roma La Sapienza, Div Gastroenterol, Dept Clin Med, Rome, Italy
[7] Hannover Med Sch, Dept Neurol, D-3000 Hannover, Germany
关键词
branched-chain amino acids; bromocriptine; hepatic cirrhosis; hepatic encephalopathy; non-absorbable antibiotics; non-absorbable disaccharides; ornithine aspartate; sodium benzoate; treatment; zinc;
D O I
10.1007/s11011-007-9060-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to the treatment of this condition, which aims at reducing ammonia production and absorption using either non-absorbable disaccharides and/or antibiotics, should be revisited, modified or even abandoned. Pros and cons of present therapeutic strategies and possible future developments were discussed at the fourth International Hannover Conference on Hepatic Encephalopathy held in Dresden in June 2006. The content of this discussion is summarized.
引用
收藏
页码:389 / 405
页数:17
相关论文
共 50 条
  • [31] Hepatic encephalopathy: From pathophysiology to treatment
    Mas, A
    DIGESTION, 2006, 73 : 86 - 93
  • [32] HEPATIC-ENCEPHALOPATHY - PATHOPHYSIOLOGY AND TREATMENT
    PERNEY, P
    POMIERLAYRARGUES, G
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1994, 18 (12): : 1069 - 1076
  • [33] Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment
    Fritz, Megan Kunka
    Mangino, Anthony A.
    Hunt, Taylor V.
    Pitcock, C. Tyler
    Dugan, Adam J.
    Karri, Kishore
    Yarra, Pradeep
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (08) : 899 - 906
  • [34] Hepatic encephalopathy after treatment with temozolomide
    Annemarie Goldbecker
    Anita Blanka Tryc
    Peter Raab
    Hans Worthmann
    Julian Herrmann
    Karin Weissenborn
    Journal of Neuro-Oncology, 2011, 103 : 163 - 166
  • [35] Management of Hepatic Encephalopathy
    Frontera, Jennifer A.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2014, 16 (06) : 1 - 37
  • [36] Management of Hepatic Encephalopathy
    Jennifer A. Frontera
    Current Treatment Options in Neurology, 2014, 16
  • [37] Combination Therapy for the Treatment and Prevention of Hepatic Encephalopathy
    Mohammad, Rima A.
    Regal, Randolph E.
    Alaniz, Cesar
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (11) : 1559 - 1563
  • [38] Economic impact of treatment options for hepatic encephalopathy
    Leevy, Carroll B.
    SEMINARS IN LIVER DISEASE, 2007, 27 : 26 - 31
  • [39] Hepatic Encephalopathy, from Diagnosis to Treatment in 2016
    Mouri, S.
    Bouzbib, C.
    El Mourabit, H.
    Schaefer, A.
    Imbert-Bismut, F.
    Galanaud, D.
    Tripon, S.
    Mallet, M.
    Rudler, M.
    Housset, C.
    Thabut, D.
    Weiss, N.
    REANIMATION, 2016, 25 (05): : 491 - 505
  • [40] Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
    Nishida, Shinya
    Hamada, Koichi
    Nishino, Noriyuki
    Fukushima, Daizo
    Koyanagi, Ryota
    Horikawa, Yoshinori
    Shiwa, Yoshiki
    Saitoh, Satoshi
    WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (06) : 531 - 541